April 2010

Editorial Board
Published in issue: April 2010
ii

Preface
• The Conference Chairmen,
• Anna Falanga,
• Benjamin Brenner,
• Frederick R. Rickles
Published in issue: April 2010
ix

Friday, April 23rd, 2010

Plenary Session 1: Risk factors for thrombosis in cancer

Emerging risk stratification approaches to cancer-associated thrombosis: risk factors, biomarkers and a risk score
• Gregory C. Connolly,
• Alok A. Khorana
Published in issue: April 2010
S1-S7
The roles of anticoagulants in patients with cancer
• Agnes Y.Y. Lee
Published in issue: April 2010
S8-S11
Tests predictive of thrombosis in cancer
• Cihan Ay,
• Ingrid Pabinger
Published in issue: April 2010
S12-S15

Debate

Thromboprophylaxis during chemotherapy: NO
• Mark N. Levine
Published in issue: April 2010
S16
Thromboprophylaxis during chemotherapy in patients with advanced cancer
• Giancarlo Agnelli,
• Melina Verso
Published in issue: April 2010
S17-S20

Saturday, April 24th, 2010

Plenary Session 2. Thromboprophylaxis in cancer patients

VTE prophylaxis for the medical patient: where do we stand? – A focus on cancer patients
• Alexander T. Cohen,
• Bharathi Nandini,
• Jack O. Wills,
• Satoshi Ota
Published in issue: April 2010
S21-S29
Potential of new anticoagulants in patients with cancer
• Jeffrey I. Weitz
Published in issue: April 2010
S30-S35

Simultaneous Session 1. Biology of blood coagulation

Tissue factor in cancer progression and angiogenesis
• Wolfram Ruf,
• Naho Yokota,
• Florence Schaffner
Published in issue: April 2010
S36-S38
Mechanisms coupling the hemostatic system to colitis-associated cancer
• Joseph S. Palumbo,
• Jay L. Degen
Published in issue: April 2010
S39-S43
Role of the tissue factor pathway in the biology of tumor initiating cells¹1Delphine Garnier and Chloe Milsom equally contributed as first authors.
• Delphine Garnier,
• Chloe Milsom,
• Nathalie Magnus,
• ...
• Jeffrey Weitz,
• Joanne Yu,
• Janusz Rak
Published in issue: April 2010
S44-S50

Simultaneous Session 2. Bleeding issues

Open issues on bleeding and thrombosis in acute promyelocytic leukemia
• Miguel A. Sanz,
• Pau Montesinos
Published in issue: April 2010
S51-S54
Bleeding complications of antiangiogenic therapy: pathogenetic mechanisms and clinical impact
• F. Elice,
• F. Rodeghiero
Published in issue: April 2010
S55-S57
Bleeding complications associated with anticoagulant therapy in patients with cancer
• Javier Trujillo-Santos,
• José Antonio Nieto,
• Ángeles Ruíz-Gamietea,
• ...
• Roberto Quintavalla,
• Manuel Monreal
• for the RIETE Investigators
Published in issue: April 2010
S58-S61

Plenary Session 3. Antitumor properties of anticoagulants

Update on the predictive value of D-dimer in patients with idiopathic venous thromboembolism
• Benilde Cosmi,
• Gualtiero Palareti
Published in issue: April 2010
S62-S65
Antimetastatic activities of heparins and modified heparins. Experimental evidence
• Lubor Borsig
Published in issue: April 2010
S66-S71
Heparanase procoagulant effects and inhibition by heparins
• Yona Nadir,
• Benjamin Brenner
Published in issue: April 2010
S72-S76
Experimental and clinical effects of anticoagulants on cancer progression
• Cornelis J.F. Van Noorden,
• Geerte L. van Sluis,
• C. Arnold Spek
Published in issue: April 2010
S77-S79

Simultaneous Session 3. Microparticles in tumor growth

Membrane microparticles in VTE and cancer
• Nigel S. Key,
• Pichika Chantrathammachart,
• Patrick W. Moody,
• Jen-Yea Chang
Published in issue: April 2010
S80-S83
Membrane microvesicles: Macromessengers in cancer disease and progression
• Donatello Castellana,
• Florence Toti,
• Jean-Marie Freyssinet
Published in issue: April 2010
S84-S88
Predictive value of tissue factor bearing microparticles in cancer associated thrombosis
• Jeffrey I. Zwicker
Published in issue: April 2010
S89-S91

Simultaneous Session 4. Thrombotic complications

The “common soil hypothesis”: Evidence from population studies?
• Maria Benedetta Donati
Published in issue: April 2010
S92-S95
Venous thromboembolism in patients with acute leukemia, lymphoma, and multiple myeloma
• Ted Wun,
• Richard H. White
Published in issue: April 2010
S96-S102
Cancer prevention and vitamin K antagonists: An overview
• Vittorio Pengo,
• Gentian Denas,
• Seena Padayattil Jose,
• Martino F. Pengo
Published in issue: April 2010
S103-S105
Thrombosis in Paroxysmal Nocturnal Hemoglobinuria – insights into the role of complement in thrombosis
• Ilene C. Weitz
Published in issue: April 2010
S106-S107

Sunday, April 25th, 2010

Plenary Session 4. Updated guidelines for prevention and treatment of VTE in cancer

Lessons from French national guidelines on the treatment of venous thrombosis and central venous catheter thrombosis in cancer patients
• Dominique Farge,
• Cecile Durant,
• Stéphane Villiers,
• ...
• Michel Marty,
• Philippe Debourdeau
• for the Groupe Francophone Thrombose et Cancer (GFTC)
Published in issue: April 2010
S108-S116
Venous thromboembolism (VTE) in cancer patients. ESMO Clinical Recommendations for prevention and management
• Mario Mandalà,
• Roberto Labianca
Published in issue: April 2010
S117-S119
Prevention and treatment of venous thromboembolism among patients with cancer: The American Society of Clinical Oncology Guidelines
• Gary H. Lyman,
• Nicole M. Kuderer
Published in issue: April 2010
S120-S127
The National Comprehensive Cancer Center Network (NCCN) guidelines on the management of venous thromboembolism in cancer patients
• Michael B. Streiff
Published in issue: April 2010
S128-S133

Simultaneous Session 5. Targeting hemostatic system as therapy for cancer

Targeting anionic phospholipids on tumor blood vessels and tumor cells
• Philip E. Thorpe
Published in issue: April 2010
S134-S137
The role of activated protein C in cancer progression
• Geerte L. van Sluis,
• Harry R. Büller,
• C. Arnold Spek
Published in issue: April 2010
S138-S142
Tissue-factor fusion proteins induce occlusion of tumor vessels
• Christian Schwöppe,
• Torsten Kessler,
• Thorsten Persigehl,
• ...
• Walter Heindel,
• Rolf M. Mesters,
• Wolfgang E. Berdel
Published in issue: April 2010
S143-S150

Simultaneous Session 6. Gender- and age-related issues

Thrombotic complications in children with haematologic malignacies
• Maria Caterina Putti,
• Maria Luigia Randi
Published in issue: April 2010
S151-S154
Cancer in males and risk of venous thromboembolism
• Jan Beyer-Westendorf,
• Sebastian Werth,
• Kai Halbritter,
• Norbert Weiss
Published in issue: April 2010
S155-S159

5th ICTHIC Abstracts: Oral Communications

OC-01 Prognostic relevance of asymptomatic venous thromboembolism in patients with cancer
• F. Dentali,
• W. Ageno,
• M. Giorgi Pierfranceschi,
• ...
• A. Venco,
• J. Vitale,
• G. Agnelli
Published in issue: April 2010
S161
OC-02 Gemcitabine with or without prophylactic weight-adjusted dalteparin (WAD) in patients with advanced or metastatic pancreatic cancer (APC): a multicentre, randomised phase IIB trial (the UK FRAGEM study)
• A. Maraveyas,
• J. Waters,
• R. Roy,
• ...
• E. Gardiner,
• J. Sgouros,
• K.R. Wedgewood
Published in issue: April 2010
S161
OC-03 Randomized phase II trial of an oral factor Xa inhibitor in patients with metastatic cancer on chemotherapy
• M.N. Levine,
• H.A. Liebman,
• C.P. Esclanate,
• ...
• D. Deitchman,
• M.C. O'Brien,
• L.M. Ramirez
Published in issue: April 2010
S161-S162
OC-04 Expression of protease activated receptor-1 and tissue factor in human cancers determined by gene expression profiling and laser capture microdissection
• C. Haslinger,
• C. Rupp,
• H. Dolznig,
• N. Schweifer,
• J. van Ryn,
• P. Garin-Chesa
Published in issue: April 2010
S162
OC-05 Inhibition of tissue factor by Ixolaris reduces primary tumor growth and metastasis in a murine model of melanoma
• A. Da Silva de Oliveira,
• L.G. Lima,
• D.E. Machado,
• ...
• L.C. Petersen,
• I.M.B. Francischetti,
• R.Q. Monteiro
Published in issue: April 2010
S162
OC-06 Frequency, types and management of bleeding episodes in acquired von Willebrand syndrome: a five-year prospective study in a cohort of 18 patients with chronic lympho-myeloproliferative disorders (LPD/MPD)
• F. Rezzonico,
• P. Bucciarelli,
• A. Artoni,
• M.T. Canciani,
• G. Cozzi,
• A.B. Federici
Published in issue: April 2010
S162
OC-07 Heparin-antagonist PMX-60056 rapidly and completely reverses heparin anticoagulation in man
• R.E. McAllister
Published in issue: April 2010
S162-S163
OC-08 Adjuvant bemiparin in small cell lung cancer: results from the ABEL study
• R. Lecumberri,
• B. Massuti,
• G. López Vivanco,
• ...
• E. González Billalabeitia,
• E. Rocha,
• on behalf of the ABEL Investigators
Published in issue: April 2010
S163
OC-09 Tissue factor-bearing particles released from tumor cells: Relationship of particle size to procoagulant activity
• J.L. Francis,
• M. Davila,
• L. Robles-Carrillo,
• A. Amirkhosravi
Published in issue: April 2010
S163
OC-10 Involvement of cancer cell-derived microparticles on thrombus formation in vivo
• G.M. Thomas,
• L. Panicot-Dubois,
• R. Lacroix,
• F. Dignat-George,
• D. Lombardo,
• C. Dubois
Published in issue: April 2010
S163
OC-11 Residual vein thrombosis (RVT) for assessing the optimal management of deep vein thrombosis in cancer patients: an interim analysis of the cancer DACUS study
• A. Malato,
• W. Ageno,
• E. Bucherini,
• ...
• P. Spadaro,
• O. Urbano,
• S. Siragusa
Published in issue: April 2010
S164
OC-12 Tissue factor phosphorylation requires protease activated receptor-2 expression: Correlation with the prognosis of human breast cancer
• L. Rydén,
• D. Grabau,
• F. Schaffner,
• P.-E. Jönsson,
• W. Ruf,
• M. Belting
Published in issue: April 2010
S164
OC-13 Enhanced expression of Mda-9/syntenin induced through the tissue-factor pathway in melanoma promotes tumor cell migration and invasion
• H. Boukerche,
• H. Aissaoui,
• C. Prévost,
• ...
• Y. Dargaud,
• P.B. Fisher,
• C. Négrier
Published in issue: April 2010
S164
OC-14 Reversible posterior leukoencephalopathy syndrome: the role of von Willebrand Factor and ADAMTS13 in children with ALL during induction therapy
• J.D.A. Carneiro,
• E.A. D'Amico,
• V. Odone-Filho,
• D.A.F. Chamone
Published in issue: April 2010
S165
OC-15 Hemostatic activation, fibrinolysis and angiogenesis are increased in patients with advanced prostate cancer (PC) and decrease in response to hormonal therapy
• J.E. Arnason,
• S. Hong,
• G.S. Dhillon,
• ...
• J. Selzer,
• D.M. Nanus,
• S.T. Tagawa
Published in issue: April 2010
S165